ACN,Accenture revenue misses estimates on lower consulting demand March 27 Accenture Plc, recently chosen as the lead contractor for the Obamacare enrollment website, reported a smaller-than-expected 1 percent rise in quarterly revenue due to lower demand in its consulting business. 
AMZN,Top Kindle exec to update on Amazon video business next weekUPDATE 1-Amazon aims for TV business with free video streaming -WSJ SAN FRANCISCO, March 27 Online retailer Amazon.com Inc plans to enter the battle for living-room viewership in the coming months, launching a free, ad-supported streaming TV service, the Wall Street Journal reported on Thursday, citing anonymous sources.  UPDATE 1-Amazon aims for TV business with free video streaming -WSJ SAN FRANCISCO, March 27 Online retailer Amazon.com Inc plans to enter the battle for living-room viewership in the coming months, launching a free, ad-supported streaming TV service, the Wall Street Journal reported on Thursday, citing anonymous sources. SAN FRANCISCO, March 27 Amazon.com Inc will hold a rare press conference in New York on April 2 amid intense speculation that it will reveal a streaming device that rivals the Apple TV and Google Chromcast.UPDATE 1-Amazon aims for TV business with free video streaming -WSJ SAN FRANCISCO, March 27 Online retailer Amazon.com Inc plans to enter the battle for living-room viewership in the coming months, launching a free, ad-supported streaming TV service, the Wall Street Journal reported on Thursday, citing anonymous sources.  
AAPL,Top Kindle exec to update on Amazon video business next weekSettlement progress seen in Silicon Valley hiring lawsuitSettlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  SAN JOSE, Calif., March 27 Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    Settlement progress seen in Silicon Valley hiring lawsuitSettlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  SAN JOSE, Calif., March 27 Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   SAN FRANCISCO, March 27 Amazon.com Inc will hold a rare press conference in New York on April 2 amid intense speculation that it will reveal a streaming device that rivals the Apple TV and Google Chromcast.Settlement progress seen in Silicon Valley hiring lawsuitSettlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  SAN JOSE, Calif., March 27 Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.Settlement progress seen in Silicon Valley hiring lawsuitUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. SAN JOSE, California Apple Inc, Google Inc and two other Silicon Valley companies are making progress toward settling a closely watched lawsuit where tech workers allege the companies conspired to avoid competing for each other's employees in order to drive down wages.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    
BAC,UPDATE 3-Bank of America to pay $9.3 bln to settle mortgage bond claimsBank of America to pay $9.3 billion to settle mortgage bond claimsFitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)    Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   WASHINGTON Bank of America agreed to pay $9.3 billion to settle claims that it sold Fannie Mae and Freddie Mac faulty mortgage bonds, helping the bank to end one of the largest legal headaches it still faced from the financial crisis.Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)     Bank of America to pay $9.3 billion to settle mortgage bond claimsFitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)    Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   WASHINGTON Bank of America agreed to pay $9.3 billion to settle claims that it sold Fannie Mae and Freddie Mac faulty mortgage bonds, helping the bank to end one of the largest legal headaches it still faced from the financial crisis.Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)    WASHINGTON, March 26 Bank of America  agreed to pay $9.3 billion to settle claims that it sold Fannie Mae and Freddie Mac faulty mortgage bonds, helping the bank to end one of the largest legal headaches it still faced from the financial crisis.Bank of America to pay $9.3 billion to settle mortgage bond claimsFitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)    Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   WASHINGTON Bank of America agreed to pay $9.3 billion to settle claims that it sold Fannie Mae and Freddie Mac faulty mortgage bonds, helping the bank to end one of the largest legal headaches it still faced from the financial crisis.Fitch: BAC Settlement with FHFA Reduces Litigation RiskBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)   BRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  (The following statement was released by the rating agency) CHICAGO, March 27 (Fitch) The settlement between Bank of America Corporation  (BAC) and the Federal Housing Finance Agency (FHFA) resolves one of BAC's  largest remaining litigation exposures and is a positive step toward reducing  these risks, according to Fitch Ratings. There is no impact to BAC's ratings  (A/F1, Outlook Negative), as positive ratings momentum is more heavily  predicated on improved earnings and capital ratios.   UndeBRIEF-U.S. magistrate judge recommends dismissal of U.S. lawsuit vs Bank of America over mortgage debtUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)  UPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group) March 27 Bank of America Corp :  * U.S. magistrate judge recommends dismissal of U.S. lawsuit against Bank ofUPDATE 2-Judge says U.S. fraud case vs Bank of America should be tossed (Adds bank defenses and mortgage losses, Obama working group)     
BAX,UPDATE 1-Market Chatter-Corporate finance press digestBaxter plans to split into two companies, spin off biotechCORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.        CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       March 27 Healthcare company Baxter International Inc said on Thursday it would separate into two companies, one that focuses on biotechnology and the other devoted to medical equipment.CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.         Baxter plans to split into two companies, spin off biotechCORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.        CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       March 27 Healthcare company Baxter International Inc said on Thursday it would separate into two companies, one that focuses on biotechnology and the other devoted to medical equipment.CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.        March 27 The following corporate finance-related stories were reported by media:Baxter plans to split into two companies, spin off biotechCORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.        CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       March 27 Healthcare company Baxter International Inc said on Thursday it would separate into two companies, one that focuses on biotechnology and the other devoted to medical equipment.CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.       Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOBaxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.      Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.Baxter plans to spin off biotech business in 2015UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.     UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter International Inc said on Thursday that it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up nearly 5 percent.UPDATE 4-Baxter plans to spin off biotech business in 2015Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.    Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   March 27 Baxter International Inc said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.Baxter plans to spin off biotech business in 2015UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Baxter International Inc  said on Thursday it would spin off its biotechnology operations into a publicly traded company by the middle of next year and focus on its core medical technology business, sending its shares up more than 4 percent.UPDATE 2-Merck names Baxter exec as CFOMerck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.Merck names Baxter exec as CFO Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.         
BLK,REUTERS SUMMIT-BlackRock picks Philippines, Indonesia as top share hunting groundFormula One investors to share a $332 million dividend - Sky March 27 The board of Formula One parent Delta Topco agreed this week to issue a $332 million dividend for last year, British broadcaster Sky News reported on its website, citing sources.  Formula One investors to share a $332 million dividend - Sky March 27 The board of Formula One parent Delta Topco agreed this week to issue a $332 million dividend for last year, British broadcaster Sky News reported on its website, citing sources. (For other news from Reuters ASEAN Summit, click on http://www.reuters.com/summit/ASEAN14)Formula One investors to share a $332 million dividend - Sky March 27 The board of Formula One parent Delta Topco agreed this week to issue a $332 million dividend for last year, British broadcaster Sky News reported on its website, citing sources.  
BA,U.S. Navy seeks more Boeing 'Growlers' to boost capabilitiesUPDATE 3-US law firm plans to bring suit against Boeing, Malaysia AirlinesU.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)       U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      (Updates with firm clarifying relationship of petitioner with passenger)U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)        UPDATE 3-US law firm plans to bring suit against Boeing, Malaysia AirlinesU.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)       U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      (Updates with firm clarifying relationship of petitioner with passenger)U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)       WASHINGTON The U.S. Navy would add two Boeing Co EA-18G Growler electronic attack fighters to each five-plane squadron on its aircraft carriers, if Congress will fund its request of $2.1 billion for 22 more of the aircraft.UPDATE 3-US law firm plans to bring suit against Boeing, Malaysia AirlinesU.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)       U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      (Updates with firm clarifying relationship of petitioner with passenger)U.S. law firm plans to bring suit against Boeing, Malaysia AirlinesANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)      ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     NEW YORK/KUALA LUMPUR A U.S.-based law firm said it expects to represent families of more than half of the passengers on board the missing Malaysian Airlines flight in a lawsuit against the carriers and Boeing Co, alleging the plane had crashed due to mechanical failure.ANA orders 70 new planes, including 20 Boeing 777-9XsUPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)     UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    TOKYO, March 27 Japan's ANA said it will buy 20 Boeing 777-9X jets as part of a 1.7 trillion yen ($16.62 billion) order of 70 planes, a relief for the U.S. planemaker which lost a major order from Japan Airlines  to arch-rival Airbus last year.UPDATE 2-Japan's ANA gives Boeing a boost with 777X orderJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)    Japan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   * Also orders 14 Dreamliners, 30 single-aisle Airbus jetsJapan's ANA gives Boeing a boost with 777X orderQatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)   Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  ANA Holdings Inc  restored Boeing Co's  momentum in a Japanese market it has long dominated by ordering 20 new generation 777X wide-body jets after a stinging defection by Japan Airlines Co  last year to rival Airbus Group NV .Qatar buys helicopters, missiles in $23 billion defense dealsUPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)  UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included) DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.UPDATE 2-Qatar buys helicopters, missiles in $23 bln arms deals * Lockheed, Raytheon also win contracts   (Adds details, in paragraphs 9-11, of additional weapons included)        
CBS,UPDATE 1-Ex-MP3tunes chief hit with estimated $41 million copyright verdictEx-MP3tunes chief hit with estimated $41 million copyright verdict NEW YORK The former chief executive of defunct online music storage firm MP3tunes was ordered to pay an estimated $41 million on Wednesday after being found liable for infringing copyrights owned by record companies and music publishers once part of EMI Group Ltd.  Ex-MP3tunes chief hit with estimated $41 million copyright verdict NEW YORK The former chief executive of defunct online music storage firm MP3tunes was ordered to pay an estimated $41 million on Wednesday after being found liable for infringing copyrights owned by record companies and music publishers once part of EMI Group Ltd. NEW YORK, March 26 The former chief executive of defunct online music storage firm MP3tunes was ordered to pay an estimated $41 million on Wednesday after being found liable for infringing copyrights owned by record companies and music publishers once part of EMI Group Ltd.Ex-MP3tunes chief hit with estimated $41 million copyright verdict NEW YORK The former chief executive of defunct online music storage firm MP3tunes was ordered to pay an estimated $41 million on Wednesday after being found liable for infringing copyrights owned by record companies and music publishers once part of EMI Group Ltd.  
CSCO,Spherix sues Cisco over switches, routers patent infringement March 27 Spherix Inc, which buys and licenses technology patents, said it filed a lawsuit against Cisco Inc alleging infringement of 11 patents Spherix acquired from Nortel Networks. 
C,Fed bars shareholder payouts from Citi, four othersUS STOCKS-Futures point to flat open after GDP data, Citi fallsUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     US STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop      US STOCKS-Futures point to flat open after GDP data, Citi fallsUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     US STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     WASHINGTON/NEW YORK The Federal Reserve on Wednesday rejected Citigroup Inc's plans to buy back $6.4 billion of shares and boost dividends, saying the bank is not sufficiently prepared to handle a potential financial crisis. |US STOCKS-Futures point to flat open after GDP data, Citi fallsUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     US STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     VideoUS STOCKS-Futures point to flat open after GDP data, Citi fallsUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     US STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop      US STOCKS-Futures point to flat open after GDP data, Citi fallsUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop     US STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS SNAPSHOT-Wall St opens flat after data; Citigroup downUS STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop    US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   NEW YORK, March 27 U.S. stocks opened flat on Thursday as the latest economic data pointed to improving conditions, though investors were reluctant to make big bets amid tensions in Ukraine and a drop in Citigroup shares.US STOCKS-Wall St dips after GDP data, Citigroup shares tumbleUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop   US STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Wall St dips after data; Citi leads financials lowerUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop  US STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop * GDP grew 2.6 pct in Q4; jobless claims unexpectedly dropUS STOCKS-Tech, financials lead market lower; S&P; negative for year * GDP grew 2.6 pct in Q4; jobless claims unexpectedly drop      
CMCSA,Comcast's Cohen to testify in U.S. Senate on Time Warner Cable mergerUPDATE 1-Comcast's Cohen to testify on Time Warner Cable merger WASHINGTON, March 27 Comcast Corp's  Executive Vice President David Cohen will testify at a hearing in the U.S. Senate on April 9 about his company's plans to buy Time Warner Cable Inc, a Comcast spokeswoman said on Thursday.  UPDATE 1-Comcast's Cohen to testify on Time Warner Cable merger WASHINGTON, March 27 Comcast Corp's  Executive Vice President David Cohen will testify at a hearing in the U.S. Senate on April 9 about his company's plans to buy Time Warner Cable Inc, a Comcast spokeswoman said on Thursday. WASHINGTON, March 27 Comcast Corp's  Executive Vice President David Cohen will testify about his company's plans to buy Time Warner Cable Inc at a hearing in the U.S. Senate on April 9, a Comcast spokeswoman said on Thursday.UPDATE 1-Comcast's Cohen to testify on Time Warner Cable merger WASHINGTON, March 27 Comcast Corp's  Executive Vice President David Cohen will testify at a hearing in the U.S. Senate on April 9 about his company's plans to buy Time Warner Cable Inc, a Comcast spokeswoman said on Thursday.  
FB,SINGAPORE PRESS-Facebook co-founder backs Singapore start-up - Straits TimesJudge tosses lawsuit against Facebook over use of minors' photosJudge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)     Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    NEW YORK, March 26 A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)      Judge tosses lawsuit against Facebook over use of minors' photosJudge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)     Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    NEW YORK, March 26 A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)     Facebook Inc co-founder and billionaire investor Eduardo Saverin has invested in Singapore start-up Nitrous.IO.Judge tosses lawsuit against Facebook over use of minors' photosJudge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)     Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    NEW YORK, March 26 A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.Judge tosses lawsuit against Facebook over use of minors' photosEuropean Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)    European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   NEW YORK A California federal judge has dismissed a proposed class action lawsuit against Facebook Inc that had accused the company of misappropriating the names and likenesses of minors who use the social network.European Factors to Watch-Shares to track U.S. dip, tech stocks in focusAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)   Andreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  PARIS, March 27 European stocks were set to dip on Thursday, halting their recovery rally and mirroring losses on Wall Street, where technology stocks such as Facebook and King Digital Entertainment Plc  sank.     At 0725 GMT, futures for Euro STOXX 50, for UK's FTSE 100, for Germany's DAX and for France's CAC were down by between 0.1-0.3 percent.     Among U.S. technology shares taking a hit on Wednesday, Facebook tumbled 6.9 percent after the social networking company said it wouldAndreessen Horowitz closes new fund after raising $1.5 blnUPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)  UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price) SAN FRANCISCO, March 27 Andreessen Horowitz, a venture capital firm that has backed Facebook and Twitter, raised $1.5 billion for a its fourth fund, the firm said in a blog post.UPDATE 1-Facebook to use satellites, drones to spread the Internet (Adds details on drones, satellites, hiring, background on Facebook and Google projects, stock price)      
FCX,Freeport closer to resuming copper exports from Indonesia-Indonesia reaches deal with Freeport over export taxREUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.    REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   JAKARTA Indonesia's government has reached a deal over export taxes with U.S. mining giant Freeport-McMoRan Copper & Gold Inc , which should resume copper shipments next month, a senior finance ministry official told Reuters on Thursday.REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.     -Indonesia reaches deal with Freeport over export taxREUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.    REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   JAKARTA Indonesia's government has reached a deal over export taxes with U.S. mining giant Freeport-McMoRan Copper & Gold Inc , which should resume copper shipments next month, a senior finance ministry official told Reuters on Thursday.REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.    JAKARTA, March 27 Freeport-McMoRan Copper & Gold Inc has received export certification in Indonesia, a government official said on Thursday, taking it a step closer to resuming shipments from the world's fifth-largest copper mine.-Indonesia reaches deal with Freeport over export taxREUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.    REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   JAKARTA Indonesia's government has reached a deal over export taxes with U.S. mining giant Freeport-McMoRan Copper & Gold Inc , which should resume copper shipments next month, a senior finance ministry official told Reuters on Thursday.REUTERS SUMMIT-Indonesia, Freeport reach tax deal; copper exports to resumeIndonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.   Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.Indonesia, Freeport deal allows copper exports to resumeREUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.  REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.REUTERS SUMMIT-Indonesia, Freeport deal allows copper exports to resume JAKARTA, March 27 Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc, allowing nearly $4 billion worth of annual copper shipments to resume as early as next month.     
GM,BRIEF-Judge to consider emergency request that GM urge drivers to stop driving vehicles recalled for ignition switchesU.S. senator urges GM to advise not driving recalled carsUPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.    UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   WASHINGTON, March 27 General Motors  should promptly warn consumers that they should not drive GM cars that have been recalled because of faulty ignition switches, which can unexpectedly turn off engines and air bags of vehicles as they are operating, U.S. Senator Richard Blumenthal said on Thursday.UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.     U.S. senator urges GM to advise not driving recalled carsUPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.    UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   WASHINGTON, March 27 General Motors  should promptly warn consumers that they should not drive GM cars that have been recalled because of faulty ignition switches, which can unexpectedly turn off engines and air bags of vehicles as they are operating, U.S. Senator Richard Blumenthal said on Thursday.UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.    March 27 General Motors Co :  * U.S. judge sets April 4 hearing to consider request that General Motors CoU.S. senator urges GM to advise not driving recalled carsUPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.    UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   WASHINGTON, March 27 General Motors  should promptly warn consumers that they should not drive GM cars that have been recalled because of faulty ignition switches, which can unexpectedly turn off engines and air bags of vehicles as they are operating, U.S. Senator Richard Blumenthal said on Thursday.UPDATE 2-U.S. senator urges GM to tell owners of recalled cars not to drive themU.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.   U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  WASHINGTON, March 27 General Motors  should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.U.S. senator urges GM to tell owners of recalled cars not to drive themGM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.  GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said. WASHINGTON General Motors should promptly warn consumers not to drive GM cars recalled because of faulty ignition switches that can unexpectedly turn off engines and air bags as the vehicles are running, U.S. Senator Richard Blumenthal said on Thursday.GM says new part number will avoid possible confusion on recall repair March 27 General Motors Co said on Thursday the replacement ignition switch it has ordered to use in a massive passenger car recall will bear a new part number, a step that "eliminates any potential confusion about which part to use in the repair," a spokesman said.     
HAL,U.S. securities class-action settlements rebound, may not lastU.S. securities class-action settlements rebound, may not last The number and size of U.S. securities class-action settlements rose in 2013, a new study shows, but the gains may not last if the U.S. Supreme Court limits investors' ability to band together to bring lawsuits.  U.S. securities class-action settlements rebound, may not last The number and size of U.S. securities class-action settlements rose in 2013, a new study shows, but the gains may not last if the U.S. Supreme Court limits investors' ability to band together to bring lawsuits. March 27 The number and size of U.S. securities class-action settlements rose in 2013, a new study shows, but the gains may not last if the U.S. Supreme Court limits investors' ability to band together to bring lawsuits.U.S. securities class-action settlements rebound, may not last The number and size of U.S. securities class-action settlements rose in 2013, a new study shows, but the gains may not last if the U.S. Supreme Court limits investors' ability to band together to bring lawsuits.  
INTC,Intel takes stake in Big Data startup ClouderaUPDATE 2-Intel takes 'significant' stake in Big Data startup ClouderaIntel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.    Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   SAN FRANCISCO, March 27 Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.     UPDATE 2-Intel takes 'significant' stake in Big Data startup ClouderaIntel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.    Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   SAN FRANCISCO, March 27 Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.    SAN FRANCISCO, March 27 Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.UPDATE 2-Intel takes 'significant' stake in Big Data startup ClouderaIntel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.    Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   SAN FRANCISCO, March 27 Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Intel takes 'significant' stake in Big Data startup ClouderaDeals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.   Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  SAN FRANCISCO Intel Corp said on Thursday it made a significant investment in Cloudera and will make the fast-growing startup its preferred distributor of software for crunching Big Data.Deals of the day- Mergers and acquisitionsSwedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.  Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported. (Adds Finnair, Cargill, SoftBank, Grupo, DIA, Intel; Updates Yahoo Japan)Swedish eye tracking technology firm Tobii plans IPO -report STOCKHOLM, March 27 Swedish eye tracking technology firm Tobii, co-owned by chipmaker Intel, is planning a stock market listing which could value the firm at around 2 billion crowns ($309 million), business daily Dagens Industri reported.     
JPM,JPMorgan defeats appeal in U.S. silver price-fixing lawsuit NEW YORK, March 27 Silver investors failed to show that JPMorgan Chase & Co conspired to drive down the metal's price, and an antitrust lawsuit accusing the largest U.S. bank of price-fixing should be dismissed, a federal appeals court ruled. 
LMT,UPDATE 2-Pentagon sees possible delay of software for Navy F-35US Navy plans competition for next-generation missileU.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.   U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  WASHINGTON, March 26 The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.    US Navy plans competition for next-generation missileU.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.   U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  WASHINGTON, March 26 The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.   WASHINGTON, March 26 The Block 3F software needed for the U.S. Navy's version of Lockheed Martin Corp's  F-35 fighter jet could be delayed by four to six months, the U.S. general who runs the $392 billion program for the Pentagon said on Wednesday.US Navy plans competition for next-generation missileU.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.   U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  WASHINGTON, March 26 The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.U.S. Navy plans competition for next-generation missileQatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.  Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up. WASHINGTON The U.S. Navy on Wednesday said it planned to launch an open competition around fiscal 2017 for a next-generation missile, seeking to reassure weapons makers they still have prospects after a separate deal with Lockheed Martin Corp for 90 air-launched missiles sparked a formal protest.Qatar buys helicopters, missiles in $23 billion defense deals DOHA Qatar announced contracts worth about $23 billion on Thursday to buy attack helicopters, guided missiles, tankers and other weapons from Boeing Co , Airbus  and other arms makers as the Gulf state accelerates its military build-up.    
MA,Wal-Mart sues Visa for $5 billion over card swipe fees March 27 Wal-Mart Stores Inc this week sued Visa Inc for $5 billion, accusing the credit and debit card network of excessively high card swipe fees, several months after the retailer opted out of a class action settlement between merchants and Visa and MasterCard Inc. 
MRK,CORRECTED-Merck appoints Baxter executive as CFOMerck appoints Baxter executive as CFOUPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   Merck appoints Baxter executive as CFOUPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  (Corrects headline to show the Baxter executive is currently with, and not a former employee of, the company. Fixes spelling in first paragraph)Merck appoints Baxter executive as CFOUPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.  UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators. Merck & Co Inc said Baxter International Inc executive Robert Davis would join as chief financial officer, effective April 23, replacing Peter Kellogg.UPDATE 2-Merck names Baxter exec as CFO March 27 Merck & Co Inc appointed Baxter International Inc executive Robert Davis as chief financial officer, as it looks to cut costs and focus on drugs that are more likely to be approved by regulators.   
MSFT,GameStop forecast disappoints as competition intensifiesMicrosoft unveils Office for Apple's iPad, as expectedUPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   SEATTLE, March 27 Microsoft Corp said its Office suite of applications, including the core Word, Excel and PowerPoint programs, will be available as an iPad app available on Apple Inc's App Store from Thursday morning.UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.     Microsoft unveils Office for Apple's iPad, as expectedUPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   SEATTLE, March 27 Microsoft Corp said its Office suite of applications, including the core Word, Excel and PowerPoint programs, will be available as an iPad app available on Apple Inc's App Store from Thursday morning.UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    GameStop Corp, the world's No. 1 retailer of videogame products, forecast full-year earnings below market expectations as more games are sold online and it faces increased competition from big retailers offering trade-ins for used games.Microsoft unveils Office for Apple's iPad, as expectedUPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.    UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   SEATTLE, March 27 Microsoft Corp said its Office suite of applications, including the core Word, Excel and PowerPoint programs, will be available as an iPad app available on Apple Inc's App Store from Thursday morning.UPDATE 4-GameStop shares fall as 2014 forecast disappointsGameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.   GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  (Updates stock price, adds details from company and CEO comment)GameStop shares fall as 2014 forecast disappointsUPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.  UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company. Video game retailer GameStop Corp on Thursday forecast full-year earnings below market expectations as it is yet to see an uptick in sagging video game software sales, despite robust hardware sales driven by the launches of Microsoft's Xbox One and Sony's PlayStation 4 consoles.UPDATE 4-Microsoft CEO signals new course with Office for iPad SAN FRANCISCO, March 27 Microsoft Corp's  new Chief Executive Officer, Satya Nadella, finally unveiled Office for Apple Inc's iPad in a polished debut that set him apart from his energetic predecessor while signaling his plans to make mobile apps the top priority at the world's largest software company.     
MS,US CFTC fines Morgan Stanley $490,000 for client fund issuesUPDATE 2-U.S. fines Morgan Stanley for not segregating client funds WASHINGTON, March 27 The Commodity Futures Trading Commission on Thursday fined Morgan Stanley  $490,000 for violating rules that require futures brokers to protect clients by keeping their money segregated from other funds on the bank's books.  UPDATE 2-U.S. fines Morgan Stanley for not segregating client funds WASHINGTON, March 27 The Commodity Futures Trading Commission on Thursday fined Morgan Stanley  $490,000 for violating rules that require futures brokers to protect clients by keeping their money segregated from other funds on the bank's books. WASHINGTON, March 27 The Commodity Futures Trading Commission on Thursday fined Morgan Stanley Smith Barney LLC $490,000 for violating rules that tell banks how to segregate client funds from other money in the bank's books.UPDATE 2-U.S. fines Morgan Stanley for not segregating client funds WASHINGTON, March 27 The Commodity Futures Trading Commission on Thursday fined Morgan Stanley  $490,000 for violating rules that require futures brokers to protect clients by keeping their money segregated from other funds on the bank's books.  
NEM,Indonesia, Freeport deal allows copper exports to resume JAKARTA Indonesia has reached a deal over export taxes with U.S. mining company Freeport-McMoRan Copper & Gold Inc , allowing nearly $4 billion worth of annual copper shipments to resume as early as next month. 
RHT,Red Hat fourth-quarter profit rises 5 pctUPDATE 2-Red Hat forecasts disappointing full-year profit * Sees 2015 rev $1.73-$1.755 bln vs est $1.76 bln   (Adds forecast; updates shares)  UPDATE 2-Red Hat forecasts disappointing full-year profit * Sees 2015 rev $1.73-$1.755 bln vs est $1.76 bln   (Adds forecast; updates shares) March 27 Red Hat Inc, the world's largest commercial distributor of the Linux operating system, reported a 5 percent rise in fourth-quarter profit as subscription revenue increased.UPDATE 2-Red Hat forecasts disappointing full-year profit * Sees 2015 rev $1.73-$1.755 bln vs est $1.76 bln   (Adds forecast; updates shares)  
V,Wal-Mart sues Visa for $5 billion over card swipe fees March 27 Wal-Mart Stores Inc this week sued Visa Inc for $5 billion, accusing the credit and debit card network of excessively high card swipe fees, several months after the retailer opted out of a class action settlement between merchants and Visa and MasterCard Inc. 
WMT,Wal-Mart sues Visa for $5 billion over card swipe fees March 27 Wal-Mart Stores Inc this week sued Visa Inc for $5 billion, accusing the credit and debit card network of excessively high card swipe fees, several months after the retailer opted out of a class action settlement between merchants and Visa and MasterCard Inc. 
